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ess: riteshpgi@gmail.coSummary The role of noninvasive ventilation (NIV) in the management of acute
respiratory distress syndrome (ARDS) is controversial. The aim of this study was to
assess the effect of NIV on the rate of endotracheal intubation and intensive care
unit (ICU) mortality in patients with ARDS. We searched the MEDLINE database for
relevant studies published from 1980 to September 2005, and included studies if (a)
the design was a randomized controlled trial; (b) patients had ARDS irrespective of
the underlying etiology; (c) the interventions compared NIV and medical therapy
with medical therapy alone; and (d) outcomes included need for endotracheal
intubation and/or ICU survival. The addition of NIV to standard care in the setting of
ARDS did not reduce the rate of endotracheal intubation (absolute risk reduction
(RR) 13.5%, 95% confidence interval (CI) 5.2% to 31.3%), and had no effect on ICU
survival (absolute RR 4.8%, 95% CI 12.8% to 22.1%). However, the trial results were
significantly heterogeneous.
Thus, current evidence suggests that patients with ARDS are unlikely to have any
significant benefits on outcome when NIV is added to standard therapy. However, this
analysis is limited by the presence of significant heterogeneity; hence large
randomized controlled trials are required to settle this issue.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Noninvasive ventilation (NIV) is the application of
ventilatory support without an invasive endotra-Elsevier Ltd. All rights reserv
2784976;
m (R. Agarwal).cheal airway. This form of ventilatory support has
been successfully applied for diverse forms of
respiratory failure.1 It not only reduces the need
for endotracheal intubation and the complications
associated with invasive ventilation but in specific
instances also decreases mortality.2,3 However, the
role of NIV in acute respiratory distress syndrome
(ARDS) is at best controversial, and there is sparseed.
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likely to benefit from NIV.4,5 One recently published
systematic review found NIV to be efficacious in
decreasing endotracheal intubation and improving
intensive care unit (ICU) survival.6 However, it did
not specifically include patients with ARDS. The aim
of this report was to systematically analyze the role
of NIV on the rates of endotracheal intubation and
ICU mortality, specifically in the subgroup of
patients with ARDS.Methods
Search strategy
We searched the National Library of Medicine’s
MEDLINE from 1980 to September 2005, for articles,
limiting the search to randomized controlled trials
and clinical trials (no language restrictions), using
the keywords: NIV, noninvasive positive pressure
ventilation, nasal ventilation, bipap, cpap, bilevel
positive airway pressure or continuous positive
airway pressure (CPAP). We reviewed the reference
lists of all identified studies and reviews, and hand-
searched our personal files.Selection criteria
We used the following criteria to select articles: (a)
study design was a randomized controlled trial; (b)
study population with ARDS, i.e. acute onset,
bilateral pulmonary infiltrates, PaO2/FiO2o200 on
room air, no clinical evidence of cardiac cause for
the pulmonary infiltrates. There were no restric-
tions on the proportion of patients with ARDS in a
specific study; (c) the intervention included NIV and
standard therapy vs. standard therapy alone; and
(d) outcomes included the need for endotracheal
intubation and ICU mortality (and if not available
hospital mortality).Data abstraction
Study description
Independently and in duplicate, two of the authors
(R.A., C.R.) abstracted data from these trials.
Information abstracted included the objective,
patient population, setting, description of method
used to apply NIV, outcomes, criteria and defini-
tions used, study results, and publication status.
Differences in opinion were settled by consensus or
after consultation with a third author.Analysis
For the clinical outcomes, we calculated the risk
difference (RD) and 95% confidence intervals (CI)
using the statistical package Review Manager (Rev-
Man; Version 4.2.8 for Windows; Oxford, England;
The Cochrane Collaboration, 2003). The RD from
individual studies was pooled using the random
effects model. We tested heterogeneity between
trials with w2 tests, with Pp0.05 indicating sig-
nificant heterogeneity. We also evaluated statisti-
cal heterogeneity using the I2 statistic, which
measures the extent of inconsistency among the
studies’ results and is interpreted as approximately
the proportion of total variation in study estimates
that is due to heterogeneity rather than sampling
error. An I2 value greater than 50% indicates
significant heterogeneity. Finally, visual inspection
of the Forest plots was also used to qualitatively
assess heterogeneity.Results
Study selection
Our initial electronic searches yielded 1098 studies.
Of these, 693 studies were excluded as they did not
evaluate NIV, 382 studies were excluded as they
evaluated NIV but not acute hypoxemic respiratory
failure and 20 trials were excluded as they involved
acute hypoxemic respiratory failure but not speci-
fically ARDS or were not randomized controlled
trials. Only three randomized controlled trials, all
fully published, met our selection criteria.7–9
Study description
All trials were prospective, randomized and had
described their treatment protocol clearly
(Table 1). Two studies had used concealed rando-
mization,7,8 but none were blinded. All studies
provided data on endotracheal intubation and ICU
and/or hospital mortality. Of the four trials, one
was a multi-center8 and two were single center
studies.7,9
No trial specifically included patients with ARDS,
and all trials included patients with varied causes
of acute hypoxemic respiratory failure but provided
data on the ARDS patients separately.7–9 The
patient populations with ARDS enrolled in these
four trials were diverse, and included immunocom-
petent7,9 and immunosuppressed patients,8 both
pulmonary7–9 and extrapulmonary causes of
ARDS.7,8 The details regarding the noninvasive
ventilators, the modes, the interfaces and the
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Table 1 Randomized controlled trials employing noninvasive ventilation in acute respiratory distress syndrome.
Study Ventilator Mode Interface Pressure used,
range (cm H2O)
Antonelli et al.7 Conventional
(Puritan Bennett
7200 ae, Siemens
Servo 900C)
Bilevel positive
airway pressure
Full face mask IPAP: 14–20
Italy EPAP: 5–10
1 center, ICU
15 patients
Solid organ
transplant
Delclaux et al.8 Non-conventional
ventilator
(VitalSigns)
Continuous positive
airway pressure
Full face mask 7.5–10
France
6 centers, ICU
81 patients
Heterogeneous
Ferrer et al.9 Non-conventional
ventilator (BiPAP
Vision)
Bilevel positive
airway pressure
Full face mask (if
not
tolerated—nasal
mask)
IPAP: 10–24
Spain EPAP: 4–12
1 center, ICU
15 patients
Heterogeneous
Role of NIV in ARDS 2237pressures used are described in Table 1. Briefly,
three studies used full-face mask,7,9 and one nasal
mask8; two studies have used noninvasive pressure
support ventilation (NIPSV), and one study had used
CPAP.8 No statistical heterogeneity was noted both
by the I2 method (o50%) and the Chi-square
method (P40.05), and by visual inspection of the
Forest plot. However, there was significant clinical
and methodological heterogeneity.
Effect of NIV on clinical outcomes
These three trials included a total of 111 patients,
and analysis showed that although the use of NIV in
ARDS showed a trend towards decreasing the
intubation rates (risk reduction [RR], 0.17; 95%
CI, 0.38 to 0.04) and ICU survival (RR, 0.04; 95%
CI, 0.2 to 0.12), this was not statistically
significant (Fig. 1).Discussion
The results of our systematic review suggest that
NIV when applied to standard medical therapy doesnot decrease the need for endotracheal intubation
(number-needed-to-treat (NNT), 8; 95% CI, 20
to 4) or ICU survival (NNT, 21; 95% CI, 8 to 5).
However, it is difficult to draw definite conclusions
as the total numbers of studies and patients were
relatively small, 3 and 111, respectively.
Importantly, the statistical tests used to assess
heterogeneity did not show presence of significant
heterogeneity. Moreover, visual inspections of the
Forest plot which can indicate the presence of
heterogeneity, even when the statistical tests fail
to detect heterogeneity, were also noncontribu-
tory. However there were significant variations in
the case-mix, use of different interfaces and modes
of NIV (CPAP vs. NIPSV), so-called clinical and
methodological heterogeneity.10
There is a strong pathophysiological basis for the
role of NIV in ARDS.4 However, there is dearth of
literature on this subject. In fact there are data to
suggest that the presence of ARDS was an indepen-
dent risk factor associated with NIV failure.11 Thus
large, properly conducted, adequately powered,
randomized controlled trials are required to settle
the issue. Assuming an intubation rate of 50% in the
standard medical therapy group, and achieving a
50% reduction rate with the use of NIV, we would
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Figure 1 Forest plot [risk reduction (RR), 95% confidence intervals (CI)] displaying the studies that have used
noninvasive ventilation specifically in acute respiratory distress syndrome. The plot shows that NIV decreases neither
the intubation rates nor the ICU survival.
R. Agarwal et al.2238require 103 patients in each group to detect these
differences (confidence level [1a] 95%, power
level [1b] 95%).
The strength of this review includes a systematic
approach to searching the literature and including
specifically patients with ARDS. Limitations of this
review include the heterogeneity of populations
enrolled in these four trials, and some uncertainty
about patient characteristics that precludes strong
conclusions.Conclusions
This systematic review suggests that application of
NIV in patients with ARDS does not decrease the
rate of endotracheal intubation or ICU survival.
Thus NIV, if tried, should be tried under trial
conditions, and as early as possible in patients with
ARDS not responding to standard medical therapy.
However, caution is advised to recognize the failure
of NIV early, with facilities for next level of
treatment, i.e. endotracheal intubation and inva-
sive ventilation being readily available. Finally,
more randomized controlled trials are required to
definitely settle the role of NIV in ARDS.References
1. Brochard L, Mancebo J, Elliott MW. Noninvasive ventilation
for acute respiratory failure. Eur Respir J 2002;19:712–21.2. Ram FSF, Picot J, Lightowler J, et al. Non-invasive positive
pressure ventilation for treatment of respiratory failure due
to exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev 2004;3:CD004104.
3. Agarwal R, Aggarwal AN, Gupta D, et al. Noninvasive
ventilation in acute cardiogenic pulmonary oedema. Post-
grad Med J 2005;81:637–43.
4. Wysocki M, Antonelli M. Noninvasive mechanical ventilation
in acute hypoxaemic respiratory failure. Eur Respir J 2001;
18:209–20.
5. Hess DR. The evidence for noninvasive positive-pressure
ventilation in the care of patients in acute respiratory
failure: a systematic review of the literature. Respir Care
2004;49:810–29.
6. Keenan SP, Sinuff T, Cook DJ, et al. Does noninvasive positive
pressure ventilation improve outcome in acute hypoxemic
respiratory failure? A systematic review. Crit Care Med
2004;32:2516–23.
7. Antonelli M, Conti G, Bufi M, et al. Noninvasive ventilation
for treatment of acute respiratory failure in patients
undergoing solid organ transplantation: a randomized trial.
JAMA 2000;283:235–41.
8. Delclaux C, L’Her E, Alberti C, et al. Treatment of acute
hypoxemic nonhypercapnic respiratory insufficiency with
continuous positive airway pressure delivered by a face
mask: A randomized controlled trial. JAMA 2000;284:
2352–60.
9. Ferrer M, Esquinas A, Leon M, et al. Noninvasive ventilation
in severe hypoxemic respiratory failure: a randomized
clinical trial. Am J Respir Crit Care Med 2003;168:1438–44.
10. Alderson P, Green S, Higgins JPT, editors. Analysing and
presenting results. Cochrane Reviewers’ handbook 4.2.2
[updated March 2004]; Section 4. The Cochrane Library,
Issue 1. Chichester, UK: Wiley; 2004. p. 68–139.
11. Antonelli M, Conti G, Moro L, et al. Predictors of failure of
noninvasive positive pressure ventilation in patients with
acute hypoxemic respiratory failure: a multi-center study.
Intensive Care Med 2001;27:1718–28.
